Designing drugs to cut acute lymphoblastic leukaemia (ALL) at its rootsProf. Olaf Heidenreich, Newcastle University and the Princess Maxima Centre for Paediatric Oncology
Global surveillance of survival from haematological malignancies in children, teenagers and young adultsProf Claudia Allemani, London School of Hygiene and Tropical Medicine
Identifying epigenetic biomarkers of early-life factors in association with childhood cancer risk.Dr Natália Spitz Toledo Dias, International Agency for Research on Cancer (IARC), part of the World Health Organisation (WHO)
Studying the synergistic effect of mycotoxins exposure and Epstein Barr virus infection in causing Burkitt’s Lymphoma in AfricaDr Grace Akinyi Odongo, International Agency for Research on Cancer (IARC), part of the World Health Organisation (WHO)
Exploiting a novel immunotherapy target for the treatment of T-cell acute lymphoblastic leukaemia (T-ALL)Dr Marc Mansour, UCL Cancer Institute
A pilot Investigation of the ZFP36L1 protein as a candidate therapeutic target in osteosarcoma cellsDr John Murphy, University of Westminster
One of the greatest medical success stories of the last century is the amazing growth in the survival from childhood cancer. Fifty years ago, only a quarter of children diagnosed with cancer survived. Today, more than 80 per cent of young patients can be successfully treated.
However, cancer still claims the lives of around 250 children every year in the UK. And unfortunately the children who survive may be left with serious health and developmental problems as a result of the intensive treatments used to save their young lives.
Through our investment in research, we are taking forward our understanding of childhood cancer, to give new insights into ways of treating young patients with even the most difficult forms of cancer. We hope to drive up the survival rate still further whilst reducing the risk of harm.